News about Clinical Trials

Evergreen Theragnostics Opens Phase II Small Cell Lung Cancer Clinical Trial in EU

The CCK2-VIEW trial uses 68Ga-EVG321, a peptide-based Radioligand imaging agent administered to patients with small cell lung cancer.

Clinical Trials | 18/10/2024 | By Aishwarya |  645

Eximia Research Acquires Integrated Clinical Trial Services

With this expansion into Iowa, this partnership marks another significant milestone in Eximia's mission to broaden access to cutting-edge clinical trials and innovative healthcare solutions across the nation.

Clinical Trials | 17/10/2024 | By Aishwarya |  613

GBI and Allterum to Manufacture Therapeutic Antibody for Clinical Trials

With this collaboration, GBI will leverage their extensive expertise in manufacturing complex biologics to ensure the high-quality production of 4A10 for Phase 1/2a clinical trials.

Clinical Trials | 08/10/2024 | By Aishwarya |  359

CD Biopharma Receives FDA Clearance for Phase I Clinical Trial of CD-001

CD-001, the company's clinical candidate, is built on its proprietary Bispecific Fusion Protein (BsFP) platform.

Clinical Trials | 20/09/2024 | By Aishwarya |  475

GC Biopharma, Hanmi Pharma Secure IND Clearance for Phase 1/2 Clinical Trial

LA-GLA is an innovative new drug for the treatment of Fabry disease as the world's first once-monthly subcutaneous treatment, which is being co-developed by GC Biopharma and Hanmi Pharmaceutical.

Clinical Trials | 03/09/2024 | By Aishwarya |  586

Sanofi Reveals Positive Results of Tolebrutinib in HERCULES Phase 3 Study

In the HERCULES study, nrSPMS was defined at baseline as having an SPMS diagnosis with an expanded disability status scale (EDSS) score between 3.0 and 6.5, no clinical relapses for the previous 24 months and documented evidence of disability accumulation in the previous 12 months.

Clinical Trials | 03/09/2024 | By Aishwarya |  637

Grit Biotechnology Secures IND Clearance for GT201 from US FDA

GT201, an advanced genetically engineered TIL product developed by Grit Biotechnology's platforms StemTexp and StaViral, boosts T cell survival and function by expressing a vital membrane-bound cytokine complex.

Clinical Trials | 02/09/2024 | By Aishwarya |  407

Mabwell Gets CDE Approval to Initiate Phase III Clinical Trial of 9MW2821

9MW2821 is a novel Nectin-4-targeting ADC independently developed by Mabwell, and it is the first of its kind in China to initiate clinical trials on the same target, with more than 400 subjects enrolled in the clinical studies for multiple indications.

Clinical Trials | 27/08/2024 | By Aishwarya |  394

WCG Acquires Array to Develop Integrated Clinical Research Training Solution

WCG has announced the acquisition of Array, a leading content engagement partner for life sciences events that offers a unique combination of data, technology, and engagement services proven to enhance business results and drive actionable insights.

Clinical Trials | 07/08/2024 | By Aishwarya |  410

Acumen Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug

Acumen Pharmaceuticals, Inc. has announced that the first subject has been dosed with a subcutaneous formulation of sabirnetug (ACU193) in a Phase 1 pharmacokinetic (PK) comparison study.

Clinical Trials | 03/08/2024 | By Aishwarya |  431